First Round News Hubb
Advertisement Banner
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
First Round News Hubb
No Result
View All Result
Home First Round News

The Capital Quest | Temasek bets on Motilal Oswal PE-backed diagnostics company

admin by admin
September 26, 2022
in First Round News


Goa-based Molbio Diagnostics, known for its ‘Truenat’ technology for real-time testing for diseases such as Covid-19 and dengue, said Monday that Singapore state investment firm Temasek has decided to invest $85 million (Rs 693 crore) in the company.

The fresh funds from Temasek, along with those from existing investors such as Motilal Oswal Alternates, will help the company accelerate development and commercialisation of new technologies based on clinical need gaps, Molbio said in a statement.

Molbio says its technology brings together a portable, battery-operated real-time polymerase chain reaction (PCR) platform that can be used for testing infectious diseases such as tuberculosis, Covid-19, Hepatitis-C, human papillomavirus, influenza as well as vector-borne diseases like dengue, chikungunya and malaria.

“The demand for high-quality, point-of-care molecular diagnostic systems is higher than ever today. The strategic partnership with Temasek will strengthen our ability to provide sustainable choices to address global healthcare challenges,” said Sriram Natarajan, Director and CEO, Molbio Diagnostics.

Molbio says its Truenat real-time PCR has been deployed in over 5,000 testing centres across over 40 countries.

In India, the government has deployed its devices at primary and community health centres across all states and Union Territories under the National Tuberculosis Elimination Program, it added.

Temasek joins the cap table two and a half years after Motilal Oswal Private Equity (MOPE), a subsidiary of financial services group Motilal Oswal Financial Services, inked a deal to invest up to Rs 240 crore ($32.75 million then) in Molbio. This was struck just before the Covid-19 pandemic hit the globe and pushed up demand for PCR testing.

Temasek has been on an investment spree in India, having clocked over a dozen transactions over the last 15 months. The Molbio deal adds to its recent bets in the healthcare sector in companies like regional hospital chain Medica Synergie and eyecare chain Dr Agarwal’s.

Related



Source link

Previous Post

Keypoint Intelligence Research Uncovers Print Buying Trends

Next Post

Not So Dark gets served with $80M to help smaller restaurants scale digitally

Next Post

Not So Dark gets served with $80M to help smaller restaurants scale digitally

Recommended

The Capital Quest | NBK Capital Partners closes new private debt fund below target

2 months ago

AI-powered recruiting startup for senior talent raises $40M funding

2 months ago

TrustRadius Enables Buyers With Comprehensive Technology

3 weeks ago

State of Israeli tech ecosystem 2022 and what to expect in 2023

3 weeks ago

RoboBurger: $10M funding for world’s first robot burger in a box

3 months ago

How AI Can Support Startups & Investors + VCs Investing in AI

1 month ago

first-round-white

© 2022 First Round News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • First Round News
  • Funding News
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact

© 2022 First Round News Hubb All rights reserved.